What is the step‑by‑step approach to diagnosing, staging, and treating lung cancer?

Step-by-Step Approach to Lung Cancer Management

The management of lung cancer follows a systematic pathway: multidisciplinary evaluation → tissue diagnosis with molecular testing → comprehensive staging → treatment based on stage and histology → surveillance for recurrence.

Initial Evaluation and Diagnosis

Clinical Assessment

Document smoking history (pack-years), performance status (0-4 scale), weight loss, and specific symptoms including hemoptysis, persistent cough, dyspnea, bone pain, or neurological symptoms 1, 2.

Diagnostic Strategy: Biopsy the Highest Stage First

Always attempt to biopsy the most advanced lesion first (suspected metastasis > mediastinal nodes > primary tumor) to simultaneously establish diagnosis and stage 1, 2.

For Central Lesions

• Bronchoscopy with TBNA is the primary approach 3
• EBUS-guided needle aspiration for mediastinal lymph node sampling 3, 4

For Peripheral Lesions

• Navigational bronchoscopy, radial EBUS, or CT-guided transthoracic needle aspiration (TTNA) 2
• TTNA preferred for outer one-third lesions 2

For Pleural Effusion

• Thoracentesis with cytology first (ultrasound-guided to reduce pneumothorax) 1
• If negative: second thoracentesis or proceed directly to image-guided pleural biopsy or thoracoscopy 1
• Pleural involvement = stage IV disease

For Suspected Metastatic Disease

• Biopsy the metastatic site if technically feasible 1, 2
• If multiple metastases make biopsy difficult, diagnose primary lung lesion by least invasive method 1

Essential Pathology Requirements

Obtain sufficient tissue for:

• Histologic subtyping (adenocarcinoma vs. squamous vs. small cell) 5, 6
• Molecular testing for non-squamous NSCLC: EGFR mutations, ALK rearrangements, ROS1, BRAF, MET, RET, KRAS 5
• PD-L1 expression testing for immunotherapy eligibility 5

---

Staging Workup

Imaging Protocol

• Contrast-enhanced CT chest and upper abdomen (mandatory) 5
• PET-CT scan for mediastinal lymph node and distant metastasis assessment (highest sensitivity) 3, 5
• Brain MRI (preferred over CT) for all patients with stage III-IV disease or neurological symptoms 5
• Bone scan only if PET-CT unavailable or specific bone symptoms 5

Mediastinal Staging Algorithm (Critical for Stage I-III)

For non-centrally located tumors with negative CT AND PET lymph nodes:

• Proceed directly to surgery 3

For suspect mediastinal lymph nodes on CT or PET (discrete, non-bulky):

1. EBUS/EUS-guided needle aspiration first 3, 4, 3
2. If negative → Mediastinoscopy (highest negative predictive value) 3, 4

For centrally located tumors or hilar lymph nodes:

• Always perform invasive mediastinal staging regardless of imaging 3

For bulky mediastinal disease:

• Tissue confirmation recommended but may proceed without if diagnosis clear 3

---

Treatment by Stage

Stage I-II (Early Stage)

Surgical Candidates

Anatomical lobectomy is the standard (superior to wedge/segment resection) 3, 4, 3

• VATS or open thoracotomy based on surgeon expertise 3, 4
• Systematic lymph node dissection per IASLC specifications 3, 4

Preoperative fitness assessment:

• FEV1 and DLCO >80% with no major comorbidities → proceed to surgery 3, 4
• FEV1 or DLCO <80% → add exercise testing (VO2max), echocardiography, cardiac risk assessment 4

Adjuvant chemotherapy indications:

• Stage II or III: Offer cisplatin-based doublet (cisplatin-vinorelbine most studied, 3-4 cycles, cumulative cisplatin 300 mg/m²) 3, 4, 3
• Stage IB with tumor >4 cm: Consider adjuvant chemotherapy 3, 4
• Do NOT use molecular markers (ERCC1, mutations) to guide adjuvant therapy 3, 4
• Do NOT use targeted agents in adjuvant setting 3, 4

Postoperative radiotherapy:

• NOT recommended for completely resected early-stage disease 3
• Consider for N2 disease after resection or incomplete surgery 3

Non-Surgical Candidates

Stereotactic ablative radiotherapy (SABR) is the treatment of choice 3, 4, 3

• Dose: biologically equivalent tumor dose ≥100 Gy 3, 4
• Safe in COPD and elderly patients 3, 4
• For tumors >5 cm or central location: conventional radical radiotherapy 3

---

Stage III (Locally Advanced)

Concurrent chemoradiotherapy is superior to sequential therapy 3

Unresectable Stage III (Standard Approach)

Concurrent cisplatin-based chemotherapy + radiotherapy 3

• Preferred regimens: cisplatin-etoposide or cisplatin-vinorelbine 3
• Carboplatin-paclitaxel acceptable if cisplatin contraindicated 3
• 2-4 cycles chemotherapy 3
• Radiotherapy: minimum biological equivalent of 60 Gy in 2.0 Gy fractions 3

If unfit for concurrent therapy:

• Sequential chemotherapy followed by radiotherapy 3
• Use short overall treatment time for radiotherapy 3

Do NOT use:

• Carboplatin-based induction before concurrent chemoradiotherapy 3
• Consolidation docetaxel or EGFR-TKI after concurrent chemoradiotherapy 3

Potentially Resectable Stage III (Selected Cases)

For single-station N2 disease:

• Either definitive chemoradiotherapy OR induction therapy followed by surgery 3
• Surgery only if complete resection by lobectomy expected 3
• Complex resections only at experienced centers 3
• PORT may be considered for N2 patients after resection 3

---

Stage IV (Metastatic)

Performance Status 0-2, Non-Squamous Histology

With actionable mutations:

• EGFR mutations: First-line EGFR TKI 5
• ALK rearrangements: First-line ALK inhibitor 5
• Test systematically for ALK, ROS1, BRAF, MET, RET 5

Without actionable mutations:

• Platinum-based doublet chemotherapy (cisplatin preferred for non-squamous with gemcitabine/taxanes) 5
• Pemetrexed preferred over gemcitabine/docetaxel for non-squamous 5
• Bevacizumab + carboplatin-paclitaxel for eligible PS 0-1 patients (exclude contraindications: hemoptysis, brain metastases, anticoagulation) 5
• Maximum 4 cycles (up to 6 if responding) 5

Performance Status 0-2, Squamous Histology

• Platinum-based doublet (avoid pemetrexed and bevacizumab) 5

Performance Status 2

• Single-agent chemotherapy (gemcitabine, vinorelbine, or taxanes) 5
• Carboplatin-based combination in selected eligible patients 5

Performance Status 3-4

• Best supportive care unless EGFR-mutated (consider TKI) 5

Elderly Patients (≥70 years)

• PS 0-2 with adequate organ function: carboplatin-based combination 5
• Others: single-agent chemotherapy 5

Second-Line Treatment

Docetaxel, pemetrexed (non-squamous only), or erlotinib improve survival 7

• Erlotinib higher response in non-smokers, women, adenocarcinoma, Asians, EGFR mutations 7

---

Follow-Up After Curative Treatment

Visit schedule:

• Every 3-6 months for 2-3 years 3
• Annually thereafter 3

Surveillance tools:

• History and physical examination 3
• Chest CT (preferred) or chest X-ray 3
• Detect treatable relapse, second primary lung cancers, treatment complications 3

Smoking cessation:

• Mandatory counseling at every visit (improves outcomes) 3
• Combine behavioral techniques with pharmacotherapy 3

---

Critical Pitfalls to Avoid

1. Never skip molecular testing in non-squamous NSCLC - delays appropriate targeted therapy 5
2. Never use pemetrexed in squamous cell carcinoma - ineffective and potentially harmful 5
3. Never give bevacizumab to squamous histology or patients with hemoptysis - risk of fatal hemorrhage 5
4. Never omit mediastinal staging for central tumors - high false-negative rate on imaging alone 3
5. Never use postoperative radiotherapy for completely resected stage I-II - worsens survival 3
6. Never use targeted agents or biomarkers to guide adjuvant therapy - no proven benefit 3, 4